A FIELD IN PROGRESS
Follow publications by their first public date. A protocol marks a question being asked; a results paper tells us what was observed. Neither a newer date nor a higher version number proves a better treatment.
An early report from Suzhou explored the three-component approach after previous treatment had failed.
SWORD independently evaluated a related radiotherapy–immunotherapy–cytokine combination in a multicenter phase II program.
A Wuhan case report examined PD-1 inhibition, SBRT and GM-CSF in a rare thyroid cancer.
This case explored PRaG after several prior systemic treatments.
The foundational phase II report investigated whether the PRaG triplet could produce responses in previously treated metastatic cancer.
The report explored a related triplet for a rare mesenchymal tumor with limited established treatment options.
A case report explored the triplet in a tumor subtype usually resistant to checkpoint-inhibitor monotherapy.
An early conference update of PRaG 2.0, which adds sequential IL-2 to the original triplet.
An early conference update of PRaG 2.0, which adds sequential IL-2 to the original triplet.
This report places PRaG within a complex sequence of surgery and systemic treatments.
A Sichuan collaboration explored a PRaG-related approach using interstitial implantation radiotherapy.
A Xi’an report explored the antibody–drug conjugate RC48 alongside PRaG after prior trastuzumab-based treatment.
This case combined RC48, radiotherapy, checkpoint inhibition and cytokines after earlier treatment failed.
The protocol examines whether thymalfasin adjusted to immune status can support a PRaG-based regimen.
The publication proposes adding intraperitoneal serplulimab to a PRaG-based regimen.
A Jiangsu case report described irradiated and nonirradiated tumor responses under a four-component regimen.
An independent multicenter study examined a related four-component radioimmunotherapy strategy.
The report explored RANKL inhibition with PRaG in a patient unable to continue chemotherapy.
An ASCO abstract reports an updated PRaG 2.0 cohort with IL-2 added to the original triplet.
An observational comparison examined three checkpoint-inhibitor-based strategies in MSS/pMMR metastatic colorectal cancer.
NeoPRAG explores a neoadjuvant strategy intended to improve the possibility of surgical resection.
A Wuxi–Shanghai report described a prolonged response after combined local and systemic treatment.
The protocol addresses the underrepresentation of very old adults in immunotherapy trials.
A Guangxi report explored PRaG following progression on previous systemic treatments.
A pooled analysis studied whether circulating immune markers could help identify patients at risk of moderate-to-severe adverse events.
This protocol examines an antibody–drug conjugate alongside radioimmunotherapy and cytokine support.
This mechanistic study illustrates that radiation-associated myeloid responses can also suppress antitumor immunity.
This report combines PRaG 5.0 with chemotherapy and subsequent chemoimmunotherapy.
The protocol adds recombinant human endostatin to PRaG 2.0 to investigate an anti-angiogenic combination.
A prospective Bengbu cohort examined a stereotactic radiotherapy-based PRaG approach and peripheral immune changes.
This retrospective series examines feasibility in older adults, a group often underrepresented in trials.
Try a broader term or reset one of the filters.